Acquiring Company
Novartis
Acquired Company
Kate Therapeutics
Switzerland
San DiegoBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth CareGeneticsTherapeuticsDescription
Novartis has announced the acquisition of California-based biotech company Kate Therapeutics, as part of its strategic expansion into gene therapy and neuromuscular disorder treatments. This move aligns with Novartis' goal to deliver innovative treatments and deepen expertise in gene therapy for various neuromuscular conditions, aiming to tap into the projected $55 billion cell and gene therapy market opportunity by 2030.
Other recent acquisitions in pharmaceuticals and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- Flashpoint Therapeutics announces $50M Partnership with KAIMRC and Clinical Pipeline Expansion (November 14, 2024)
- Organon successfully acquires Dermavant Sciences Ltd. to expand dermatology portfolio (October 28, 2024)
- OraSure Technologies completes acquisition of Sherlock Biosciences, Inc. to expand its innovation pipeline in molecular testing market (December 19, 2024)
- Novo Holdings completes acquisition of Catalent, Inc. (December 18, 2024)
- Lupin Limited strengthens diabetes portfolio with acquisition of three key trademarks from Boehringer Ingelheim International GmbH (December 15, 2024)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Kate Therapeutics?
Kate Therapeutics was acquired by Novartis, based in Switzerland. The deal was reported on November 21, 2024. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire Kate Therapeutics?
Novartis's acquisition of Kate Therapeutics was reported on November 21, 2024. Novartis has announced the acquisition of California-based biotech company Kate Therapeutics, as part of its strategic expansion into gene therapy and neuromuscular disorder treatments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Kate Therapeutics do?
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.